The battle against 'bad' cholesterol has just gained a new weapon: Lipfendra, the world's first oral PCSK9 inhibitor. Merck's latest development promises to bring relief to millions of people living with high LDL cholesterol, offering an alternative to statins that have been the primary treatment for decades.
For years, statins have helped manage cholesterol levels, but they're not without their drawbacks. Many patients experience side effects such as muscle aches, and for others, they just don't do enough to meet recommended health guidelines. In fact, Dr Paja Banka, associate vice-president for global clinical development at Merck, notes that "70 per cent of patients are not getting to their LDL goal". This is where Lipfendra comes in – designed to be used alongside statins or on its own for those struggling to reach their target LDL levels or experiencing adverse reactions to existing treatments.
Trials have shown promising results, with minimal side effects and a notable reduction in LDL levels. According to the data, Lipfendra can lower LDL levels to as low as 50 or 60 mg/dL – and even lower in some cases. For those at risk of heart attacks and strokes, achieving this level is crucial: high LDL cholesterol is a major contributor to atherosclerotic cardiovascular disease (ASCVD), a condition where plaque builds up in the arteries.
The NHS's own guidelines recommend that individuals with borderline or intermediate risk aim for an LDL level below 100 mg/dL. Those at higher risk should target levels of less than 70 mg/dL, while very high-risk patients should aim for less than 55 mg/dL to prevent cardiac events. Lipfendra could be a game-changer in these efforts.
While the initial price tag may seem steep – $10.50 per day or over $300 a month – Merck hopes that actual costs will be lower for many patients. With availability set to launch within weeks, it's an exciting development in the fight against high cholesterol globally.